Symbols

PRTA

Prothena·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 4

Bearish signal 2

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

Significant Revenue Decline

EPS Beats Expectation

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About PRTA

Prothena Corporation Plc

A late-stage clinical biotechnology company that develops therapeutics for AL and AA forms of amyloidosis, Parkinson's disease and inflammatory diseases

Industry

Biological Technology

Established Date

09/26/2012

Listing Date

12/21/2012

Exchange

NASDAQ Stock Exchange

Full-time Employees

163

Fiscal Year Ends

12-31

Website

www.prothena.com

Security Type

Common stock

Office address

77 Sir John Rogerson’s Quay, Block C, Grand Canal Docklands, Dublin 2, D02 VK60, Ireland

Business

Introduction

Prothena Corporation plc was incorporated under the laws of Ireland on 26 September 2012 and re-registered as an Irish public limited company on 25 October 2012. The company is a late-stage clinical biotechnology company with expertise in protein disorders and a range of investigational therapies that have the potential to alter the course of disruptive neurodegenerative diseases and rare peripheral amyloid diseases. The company's wholly-owned projects include birtamimab for the potential treatment of AL amyloidosis, and a series of projects for the potential treatment of Alzheimer's disease, including PRX012 for β-amyloid (Aβ) and the new Aβ-tau dual vaccine PRX123.

Company Financials

EPS

PRTA has released its 2025 Q3 earnings. EPS was reported at -0.68, versus the expected -0.54, missing expectations. The chart below visualizes how PRTA has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

PRTA has released its 2025 Q3 earnings report, with revenue of 2.42M, reflecting a YoY change of 148.97%, and net profit of -36.54M, showing a YoY change of 38.07%. The Sankey diagram below clearly presents PRTA's revenue sources and cost distribution.